Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
glp-1 obesity drug news today october 16 2025 gains meet modest dip truemed-eligible-subscription Medication:Tirzepatide (GLP-1 + GIP) Novartis GLP-1 Receptor Agonist
Novartis GLP-1 Receptor Agonist Diabetes Weight Management *KBu5lCaxE*
Key differential aspects of the group of glucagon-like peptide-1 receptor agonist drugs There are several arGLP-1 s approved or under study for the use in DM2: exenatide (exenatide and exenatide LAR or weekly), liraglutide, lixisenatide, dulaglutide, semaglutide, albiglutide (withdrawn from the market), and efpeglenatide (in clinical development)
truemed-eligible-subscription
Medication:Tirzepatide (GLP-1 + GIP)
Specifically, the HR for HHF was 0.20 (95% CI 0.07–0.60) with GLP-1RAs and 0.77 (95% CI 0.64–0.92) without GLP-1RAs ( P -value for interaction 0.014)
US$ 23.37
US$ 22.81
US$ 29.09
US$ 21.66
US$ 20.01
US$ 28.15
US$ 27.22
US$ 26.42
US$ 22.97
